FDA Approves Device That May Offer Alternative to Open-Heart Surgery
Primary effectiveness of no additional surgical or interventional procedures related to the device and acceptable heart blood flow function at 6 months, was achieved by 89.2%.
All articles by Steve Duffy
Haymarket Medical Network Joins Ad Council Private Marketplace
Haymarket Medical Network, a part of business media company Haymarket Media, Inc., is proud to join the Ad Council’s first ever Private Marketplace (PMP) along with other partners Cadreon, The Trade Desk and Acxiom.
ABIM Relaxes MOC Requirements Due to COVID-19
The American Board of Internal Medicine (ABIM) announced that certified physicians who have a Maintenance of Certification (MOC) requirement due in 2020 will now have until the end of 2021 to complete it.
Trulicity Approved to Reduce Risk for Major Adverse Cardiovascular Events
Remunity is indicated for continuous subcutaneous delivery of Remodulin to treat pulmonary arterial hypertension in patients ≥22 years of age.
Exebacase Gains Breakthrough Therapy Status for MRSA Bacteremia, Including Right-Sided Endocarditis
The designation is based on data from a phase 2 trial that included 116 patients with confirmed Staphylococcus aureus bacteremia including endocarditis.
Trial Evaluating Epanova for MACE Risk Reduction Discontinued
AstraZeneca is discontinuing a phase 3 trial evaluating Epanova in patients with mixed dyslipidemia who are at high risk of CVD.
Haymarket Medical Education Receives Interprofessional Joint Accreditation for the Healthcare Team
Caroline O. Pardo, Ph.D., General Manager for Haymarket Medical Education, is pleased to announce that HME, based in Paramus, NJ, has been accredited as a provider of interprofessional continuing education by the Accreditation Council for Continuing Medical Education, the Accreditation Council for Pharmacy Education, and the American Nursing Credentialing Center.
Rilonacept Gets Breakthrough Therapy Status for Recurrent Pericarditis
The FDA has granted Breakthrough Therapy designation to rilonacept for the treatment of recurrent pericarditis.
Vericiguat Reduces Risk for Heart Failure Hospitalization, CV Death in HFrEF
Vericiguat (Merck and Bayer) reduced the risk of heart failure hospitalization or cardiovascular death in patients with worsening chronic heart failure, according to new phase 3 data.
FDA Fast-Tracks Therapy for Patients at Risk for AKI After CABG
The FDA has granted Fast Track designation to ASP1128, an investigational treatment for patients at increased risk of developing moderate to severe AKI after CABG and/or valve surgery.
- Loading...
Loading...
Loading... 
Loading...